130 related articles for article (PubMed ID: 36537564)
21. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
[TBL] [Abstract][Full Text] [Related]
22. Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia: A Report from the Japan Society for Hematopoietic Cell Transplantation.
Yoshida N; Sakaguchi H; Yabe M; Hasegawa D; Hama A; Hasegawa D; Kato M; Noguchi M; Terui K; Takahashi Y; Cho Y; Sato M; Koh K; Kakuda H; Shimada H; Hashii Y; Sato A; Kato K; Atsuta Y; Watanabe K;
Biol Blood Marrow Transplant; 2020 May; 26(5):902-910. PubMed ID: 31790827
[TBL] [Abstract][Full Text] [Related]
23. Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):345-355.e7. PubMed ID: 31014757
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma.
Vassal G; Tranchand B; Valteau-Couanet D; Mahé C; Couanet D; Schoeppfer C; Grill J; Kalifa C; Hill C; Ardiet C; Hartmann O
Bone Marrow Transplant; 2001 Mar; 27(5):471-7. PubMed ID: 11313680
[TBL] [Abstract][Full Text] [Related]
25. Post-Transplant CD34
Chandra S; Bleesing JJ; Jordan MB; Grimley MS; Khandelwal P; Davies SM; Edwards S; Leemhuis T; Marsh RA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1527-1529. PubMed ID: 29555312
[TBL] [Abstract][Full Text] [Related]
26. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
Rodriguez R; Nakamura R; Palmer JM; Parker P; Shayani S; Nademanee A; Snyder D; Pullarkat V; Kogut N; Rosenthal J; Smith E; Karanes C; O'Donnell M; Krishnan AY; Senitzer D; Forman SJ
Blood; 2010 Feb; 115(5):1098-105. PubMed ID: 19965688
[TBL] [Abstract][Full Text] [Related]
27. Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan.
Ritchie DS; Morton J; Szer J; Roberts AW; Durrant S; Shuttleworth P; Grigg AP
Biol Blood Marrow Transplant; 2003 Jul; 9(7):435-42. PubMed ID: 12869957
[TBL] [Abstract][Full Text] [Related]
28. Improved survival after single-unit cord blood transplantation using fludarabine and melphalan-based reduced-intensity conditioning for malignant lymphoma: impact of melphalan dose and graft-versus-host disease prophylaxis with mycophenolate mofetil.
Sakatoku K; Kim SW; Okamura H; Kanaya M; Kato K; Yamasaki S; Uchida N; Kobayashi H; Fukuda T; Takayama N; Ishikawa J; Nakazawa H; Sakurai M; Ikeda T; Kondo T; Yoshioka S; Miyamoto T; Kimura T; Ichinohe T; Atsuta Y; Kondo E
Ann Hematol; 2022 Dec; 101(12):2743-2757. PubMed ID: 36195679
[TBL] [Abstract][Full Text] [Related]
29. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.
Shimoni A; Hardan I; Shem-Tov N; Rand A; Herscovici C; Yerushalmi R; Nagler A
Leukemia; 2007 Oct; 21(10):2109-16. PubMed ID: 17690701
[TBL] [Abstract][Full Text] [Related]
30. A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis.
Piñana JL; Perez-Pitarch A; Garcia-Cadenas I; Barba P; Hernandez-Boluda JC; Esquirol A; Fox ML; Terol MJ; Queraltó JM; Vima J; Valcarcel D; Ferriols-Lisart R; Sierra J; Solano C; Martino R
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1177-1185. PubMed ID: 28396159
[TBL] [Abstract][Full Text] [Related]
31. Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell Transplantation.
Li S; Dvorak CC; Lu Y; Chan D; Gobburu JVS; Long-Boyle J; Apsel Winger B
J Clin Pharmacol; 2022 Jul; 62(7):873-882. PubMed ID: 35048362
[TBL] [Abstract][Full Text] [Related]
32. Fludarabine/Melphalan 100 mg/m
Park HS; Lee JH; Lee JH; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1116-1121. PubMed ID: 30508593
[TBL] [Abstract][Full Text] [Related]
33. Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning.
Kutzke JL; Merten JA; Pawlenty AG; Barreto EF; Bartoo GT; Mara KC; Litzow MR; Hogan WJ; Shah MV; Mangaonkar AA; Leung N; Alkhateeb HB
Blood Adv; 2022 Jul; 6(13):3844-3849. PubMed ID: 35522968
[TBL] [Abstract][Full Text] [Related]
34. Reduced-Intensity Conditioning with Fludarabine, Melphalan, and Total Body Irradiation for Allogeneic Hematopoietic Cell Transplantation: The Effect of Increasing Melphalan Dose on Underlying Disease and Toxicity.
Chen GL; Hahn T; Wilding GE; Groman A; Hutson A; Zhang Y; Khan U; Liu H; Ross M; Bambach B; Higman M; Neppalli V; Sait S; Block AW; Wallace PK; Singh AK; McCarthy PL
Biol Blood Marrow Transplant; 2019 Apr; 25(4):689-698. PubMed ID: 30300731
[TBL] [Abstract][Full Text] [Related]
35. Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation.
Mizuno K; Dong M; Fukuda T; Chandra S; Mehta PA; McConnell S; Anaissie EJ; Vinks AA
Clin Pharmacokinet; 2018 May; 57(5):625-636. PubMed ID: 28918602
[TBL] [Abstract][Full Text] [Related]
36. Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.
Robin M; Porcher R; Wolschke C; Sicre de Fontbrune F; Alchalby H; Christopeit M; Cassinat B; Zabelina T; Peffault de Latour R; Ayuk F; Socié G; Kröger N
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1206-1211. PubMed ID: 26970380
[TBL] [Abstract][Full Text] [Related]
37. A Conditioning Regimen with Plerixafor Is Safe and Improves the Outcome of TCRαβ
Balashov D; Laberko A; Shcherbina A; Trakhtman P; Abramov D; Gutovskaya E; Kozlovskaya S; Shelikhova L; Novichkova G; Maschan M; Rumiantsev A; Maschan A
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1432-1440. PubMed ID: 29550630
[TBL] [Abstract][Full Text] [Related]
38. Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Truscott L; Pariury H; Hanmod S; Davini M; de la Maza M; Sapp LN; Staples K; Proytcheva M; Katsanis E
Pediatr Blood Cancer; 2023 Feb; 70(2):e30102. PubMed ID: 36394072
[TBL] [Abstract][Full Text] [Related]
39. Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab.
Marsh RA; Fukuda T; Emoto C; Neumeier L; Khandelwal P; Chandra S; Teusink-Cross A; Vinks AA; Mehta PA
Biol Blood Marrow Transplant; 2017 Apr; 23(4):635-641. PubMed ID: 28089878
[TBL] [Abstract][Full Text] [Related]
40. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
